Trial Condition(s):

Carcinoma, Renal Cell, Carcinoma, Renal Cell (Advanced)

Patient characteristics in advanced renal cell carcinoma and daily practice treatment with Nexavar

Bayer Identifier:

14686

ClinicalTrials.gov Identifier:

NCT00895674

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.

Inclusion Criteria
- Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Sorafenib
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information

Trial Summary

Enrollment Goal
2840
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, France

Status
Completed
 
Locations

Investigative Site

Many Locations, Netherlands

Status
Completed
 
Locations

Investigative Site

Many Locations, Argentina

Status
Completed
 
Locations

Investigative Site

Many Locations, Greece

Status
Completed
 
Locations

Investigative Site

Many Locations, Slovakia

Status
Completed
 
Locations

Investigative Site

Many Locations, South Korea

Status
Completed
 
Locations

Investigative Site

Many Locations, Philippines

Status
Completed
 
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 
Locations

Investigative Site

Many Locations, Poland

Status
Completed
 
Locations

Investigative Site

Many Locations, Mexico

Status
Completed
 
Locations

Investigative Site

Many Locations, Sweden

Status
Completed
 
Locations

Investigative Site

Many Locations, Czech Republic

Status
Completed
 
Locations

Investigative Site

Many Locations, Austria

Status
Completed
 
Locations

Investigative Site

Many Locations, Colombia

Status
Completed
 
Locations

Investigative Site

Many Locations, Russia

Status
Completed
 
Locations

Investigative Site

Many Locations, China

Status
Completed
 
Locations

Investigative Site

Many Locations, Indonesia

Status
Completed
 
Locations

Investigative Site

Many Locations, Slovenia

Status
Completed
 

Trial Design